Aspire Biopharma Holdings (ASBP) Non Operating Income (2022 - 2026)

Aspire Biopharma Holdings (ASBP) has reported Non Operating Income for 5 consecutive years, with $1.4 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Non Operating Income rose 219.36% year-over-year to $1.4 million in Q2 2026; TTM through Jun 2026 was -$3.7 million, a 131.4% decrease from a year earlier, with the FY2025 full-year figure at -$5.1 million, down 5134.88% from the prior year.
• Non Operating Income was $1.4 million for Q2 2026 at Aspire Biopharma Holdings, up from -$1.6 million in the prior quarter.
• Over five years, Non Operating Income peaked at $3.2 million in Q1 2023 and troughed at -$2.9 million in Q4 2025.
• A 5-year average of $298685.1 and a median of $153639.5 in 2023 frame the typical range for Non Operating Income.
• Across the five-year window, Non Operating Income surged 14844.13% in 2023 and tumbled 1066.86% in 2025, its largest moves.
• Over 5 years, Non Operating Income stood at $2.5 million in 2022, then plunged by 90.11% to $251702.0 in 2023, then sank by 140.22% to -$101246.0 in 2024, then slumped by 2723.13% to -$2.9 million in 2025, then soared by 149.33% to $1.4 million in 2026.
• The last three Non Operating Income figures came in at $1.4 million (Q2 2026), -$1.6 million (Q1 2026), and -$2.9 million (Q4 2025), per Business Quant data.